详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Ticagrelor versus clopidogrel in Chinese patients with coronary artery disease: a retrospective real-world study

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Cardiovascular Surgery, The First Medical Center of the PLA General Hospital, Beijing, 100853, P.R. China. [2]Department of Cardiothoracic Surgery, Xiongan Xuanwu Hospital, Xiongan New Area, 071702, Hebei Province, P.R. China. [3]Medical School of Chinese PLA, Beijing, 100039, P.R. China. [4]Department of Cardiothoracic Surgery, The 901 Hospital of PLA Joint Logistic Support Force, Hefei, 230031, Anhui Province, P.R. China. [5]Department of Adult Cardiovascular Surgery, The Sixth Medical Center of the PLA General Hospital, Beijing, 100048, P.R. China.

出处：

DOI：

关键词： Coronary artery disease DAPT Ticagrelor Clopidogrel Bleeding Aspirin

摘要：

This study compares ticagrelor and clopidogrel on major adverse cardiovascular events (MACE) and bleeding risk in Chinese CAD patients. Conducted at the Chinese PLA General Hospital from June 2017 to October 2020, it involved patients on DAPT, divided into A + C (aspirin + clopidogrel) and A + T (aspirin + ticagrelor) groups. The primary endpoint was MACE, including all-cause mortality, non-fatal myocardial infarction, and stroke. The secondary endpoint was BARC type 2, 3, and 5 bleeding events. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) adjusted confounders. Weighted outcomes and Cox models assessed treatment and outcomes. Of 844 patients, 631 were in A + C (470 males, median age 65) and 213 in A + T (178 males, median age 60). Covariates balanced using IPTW or PSM showed no significant baseline differences (P > 0.05, SMD < 0.2). No significant differences in MACE or BARC type 3/5 bleeding were found between groups. However, the A + T group had a higher risk of BARC type 2 bleeding (HR: 4.16, 95% CI: 2.18-7.90). The incidence rates of MACE events were 2.38% (15/631) in the A + C group and 3.29% (7/213) in the A + T group. This study indicates ticagrelor and clopidogrel have similar MACE and BARC type 3/5 bleeding incidence, but ticagrelor shows higher BARC type 2 bleeding risk.© 2025. The Author(s).

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

大类 | 3 区综合性期刊

小类 | 3 区综合性期刊

最新[2025]版：

大类 | 3 区综合性期刊

小类 | 3 区综合性期刊

第一作者：

第一作者机构： [1]Department of Cardiovascular Surgery, The First Medical Center of the PLA General Hospital, Beijing, 100853, P.R. China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Adding clopidogrel to aspirin after TIA or minor ischemic stroke reduced stroke without increasing bleeding [2]Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial [3]Comparison of Dual Antiplatelet Therapy with Clopidogrel and Ticagrelor in Patients with Acute Coronary Syndrome at High Risk of Bleeding [4]GENDER DIFFERENCES OF ASPIRIN RESISTANCE IN PATIENTS WITH CORONARY ARTERY DISEASE [5]Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes) [6]Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack [7]Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source [8]COST-EFFECTIVENESS OF CLOPIDOGREL-ASPIRIN VERSUS ASPIRIN ALONE FOR ACUTE TIA AND MINOR STROKE [9]替格瑞洛的安全性分析 [10]Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention